Legal News

Life Sciences weekly highlights—16 January 2020

Life Sciences weekly highlights—16 January 2020
Published on: 16 January 2020
Published by: LexisPSL
  • Life Sciences weekly highlights—16 January 2020
  • In this issue:
  • Intellectual property
  • Gilead’s SPC for HIV treatment invalid as not ‘protected by a basic patent in force’ (Teva v Gilead)
  • Unitary Patent package set to become operational by the end of 2020
  • Manufacture, marketing and sale
  • European Commission publishes medical devices nomenclature guidance documents
  • MedTech Europe warns of challenges posed by the new Medical Devices Regulation
  • International standard for side effects reporting to be mandatory from June 2022
  • Research and development
  • More...

Article summary

This week's edition of Life Sciences weekly highlights includes analysis of the Court of Appeal’s judgment that Gilead’s SPC for HIV treatment is invalid, updates on the MedTech Europe’s document on the implementation status of the EU Medical Devices Regulation, guidance documents on the medical devices nomenclature, the progress of the UK Life Sciences Industrial Strategy, and news that the Unitary Patent package is expected to become operational by the end of 2020. or take a trial to read the full analysis.

Popular documents